Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

• Type of Material: Article
• Authors: Lisa M. Lima, Emory University; Martha Arellano, Emory University; Stacie Holloway, Emory University; Marian Shepard, Emory University; Stephanie McMillan, Emory University; H Jean Khoury, Emory University
• Language: English
• Date: 2010-09-10
• Publisher: Dove Medical Press
• Publication Version: Final Published Version
• Copyright Statement: © 2010 Lima et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
• License: Creative Commons Attribution-Noncommercial 3.0 Unported
• Final Published Version (URL): http://www.dovepress.com/efficacy-of-dasatinib-for-the-treatment-of-intractable-chronic-myeloid-peer-reviewed-article-JBM
• Title of Journal or Parent Work: Journal of Blood Medicine
• ISSN: 1179-2736
• Volume: 2010
• Issue: 1
• Start Page: 221
• End Page: 225
• Keywords: outcomes; dasatinib; resistant CML
• Research Categories: Health Sciences, Oncology

Abstract

Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.